Search

Search Constraints

You searched for: Author/Creator Ansell, Stephen M.

Search Results

1. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Issue 9 (2nd September 2018)

2. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma. Issue 7 (12th June 2013)

3. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Issue 8 (August 2013)

4. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial. (2nd December 2015)

5. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. (9th September 2016)

8. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. Issue 11 (7th September 2021)

9. Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Issue 14 (5th December 2020)

10. Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia. Issue 8 (22nd May 2021)